Retatrutide is a novel synthetic peptide designed to simultaneously activate three key metabolic hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and the glucagon receptor. This tri-agonist profile has made it a subject of growing interest in metabolic, endocrinology, and obesity-related research.
In laboratory and preclinical research settings, retatrutide is studied for its effects on appetite signaling, energy expenditure pathways, glucose regulation, and lipid metabolism. Its multi-receptor activity allows researchers to investigate how combined incretin and glucagon signaling influences systemic metabolic balance and cellular energy utilization.
Research involving retatrutide focuses on receptor interactions, downstream signaling cascades, and metabolic regulation mechanisms rather than therapeutic or clinical application.
